Ms. Tan Li is Vice President at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or “Hepalink”), where she as a co-founder, leads corporate strategies, strategic transformation, enterprise resource allocation, and facilitating corporate-wide strategic initiatives.

Since founding in 1998, Hepalink has witnessed tremendous growth under the leadership of its senior executive team in which Ms. Li is a key member, achieving consistent profitability and the due-listing in mainland China and Hong Kong. Hepalink’s enoxaparin sodium injections, the company’s lead product and the first enoxaparin biosimilar in China and the EU, are being sold to more than 40 countries and regions, winning widespread recognition in markets with high-entry requirements such as the U.S. and the EU.

Ms. Li has also made substantial contribution to the strategic transformations of Hepalink, and played a pivotal role in formulating and building the company’s tri-engine business model driven by the three core businesses in heparin industrial chain, CDMO services in large molecule biologics, and the acquisition, development and commercialization of innovative drugs.

Due to her exceptional leadership at Hepalink, Ms. Li was named a Chinese Woman in Tech by Forbes, a finalist of the 2020 Forbes China Top Businesswomen List, and a recipient of the 2021 Forbes China Best Businesswomen Award.

Prior to co-founding Hepalink, Ms. Li was Deputy Chief Engineer and Deputy General Manager of Chongqing Tongda Biological Products Co., Ltd.

Ms. Li obtained a Bachelor in Science degree from Sichuan University.